Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 4.88% is 38% below its 4-year average of 7.85%, near the low end of its 4-year range (1.23%–15.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 51.89% above its 12-month average of 3.22%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 4.88%.
RETURN ON EQUITY (ROE)
4.88%
RETURN ON EQUITY (ROE) AVG TTM
3.22%
RETURN ON EQUITY (ROE) AVG 3Y
6.25%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+51.89%
CURRENT VS 3Y AVG
-21.81%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.80%
median of 338 covered companies
CURRENT VS SECTOR MEDIAN
+116.95%
vs the sector median at left
Astrana Health, Inc.
Market Cap
$1.83B
Return on Equity (ROE)
4.88%
TTM Avg
3.22%
3Y Avg
6.25%
5Y Avg
N/A
Market Cap
$1.87B
Return on Equity (ROE)
-40.09%
TTM Avg
4.56%
3Y Avg
-13.84%
5Y Avg
-2.18%
Market Cap
$1.78B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
Market Cap
$1.78B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.89B
Return on Equity (ROE)
12.01%
TTM Avg
-4.52%
3Y Avg
-16.89%
5Y Avg
-11.36%
Market Cap
$1.76B
Return on Equity (ROE)
15.35%
TTM Avg
-64.31%
3Y Avg
-71.44%
5Y Avg
-70.74%
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.95B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.18%
3Y Avg
-54.84%
5Y Avg
-44.72%
Market Cap
$1.96B
Return on Equity (ROE)
-179.99%
TTM Avg
-188.10%
3Y Avg
28.98%
5Y Avg
-2.67%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Astrana Health, Inc. (ASTH) | $1.83B | 4.88% | 3.22% | 6.25% | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -40.09% | 4.56% | -13.84% | -2.18% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | N/A | 36.48% | 36.48% | 36.48% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -54.96% | -60.50% | -51.30% | -42.73% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 15.35% | -64.31% | -71.44% | -70.74% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Absci Corporation (ABSI)vs › | $1.95B | -49.19% | -59.18% | -54.84% | -44.72% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | -179.99% | -188.10% | 28.98% | -2.67% |
| Azenta, Inc. (AZTA)vs › | $1.97B | -8.14% | -6.28% | -6.47% | -2.03% |
ROE
4.9%
ROA
1.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 4.88% |
| 2026-03-31 | 3.78% |
| 2025-12-31 | 2.89% |
| 2025-09-30 | 1.23% |
| 2025-06-30 | 3.30% |
| 2025-03-31 | 4.70% |
| 2024-12-31 | 6.05% |
| 2024-09-30 | 8.86% |
| 2024-06-30 | 10.08% |
| 2024-03-31 | 9.55% |
| 2023-12-31 | 9.89% |
| 2023-09-30 | 7.71% |
| 2023-06-30 | 8.28% |
| 2023-03-31 | 8.15% |
| 2022-12-31 | 8.53% |
| 2022-09-30 | 12.28% |
| 2022-06-30 | 15.37% |
| 2022-03-31 | 15.71% |
